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1. Introduction
Improvements in burn care have led to longer survival but
have extended hospital stays. Patients who perish after
surviving the initial burn insult and resuscitation are most
likely to die from infectious complications [1]. Burn patients
are relatively immunosuppressed and are at high risk of
infections, in particular with nosocomially-acquired multi-
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Background: Topical antimicrobials are employed for prophylaxis and treatment of burn
wound infections despite no established susceptibility breakpoints, which are becoming
vital in an era of multidrug-resistant (MDR) bacteria. We compared two methods of
determining topical antimicrobial susceptibilities.
Methods: Isolates of Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus
(MRSA), extended spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae, and
Acinetobacter baumanii-calcoaceticus (ABC) from burn patients were tested using broth micro-
dilution and agar well diffusion to determine minimum inhibitory concentrations (MICs)
and zones of inhibition (ZI). Isolates had systemic antibiotic resistance and clonality
determined. MDR included resistance to antibiotics in three or more classes.
Results: We assessed 22 ESBL-producing K. pneumoniae, 20 ABC (75% MDR), 20 P. aeruginosa
(45% MDR), and 20 MRSA isolates. The most active agents were mupirocin for MRSA and
mafenide acetate for the gram-negatives with moderate MICs/ZI found with silver sulfa-
diazene, silver nitrate, andhoney.MDRandnon-MDR isolates had similar topical resistance.
There was no clonality associated with resistance patterns.
Conclusion: Despite several methods to test bacteria for topical susceptibility, no defined
breakpoints exist and standards need to be established. We recommend continuing to use
silver products for prophylaxis against gram-negatives andmafenide acetate for treatment,
and mupirocin for MRSA.
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drug-resistant (MDR) organisms [2]. Burns result in loss of the
first line of immunologic defense, the skin, and burn eschar is
avascular. This can result in an increased risk for bacterial
colonization and subsequent invasion, which can ultimately
result in burnwound infection. Thismay be difficult to control
due to difficulty immune cells and systemic antibiotics have in
arriving to an avascular site [3]. Burn wound infections are a
significant and serious complication occurring after thermal
injury. Though the rate of burn wound infections has
decreased, burn wound sepsis remains a substantial source
of infection in this population [4].
Improvements in burn wound care, such as early excision
and grafting, have resulted in decreased mortality [5]. Early
excision and grafting is the standard of care at specialized burn
centers in the United States. The benefit of topical antimicro-
bials, however, is that they can be used at all levels of care, even
when surgery for excision and grafting is not available. Topicals
such as honey have been in use since antiquity, and others for
decades[4–11].Therearebothanimalstudiesandclinicalstudies
that provide data about the morbidity and mortality benefits
associatedwithuseofvarioustopicalantimicrobialagents inthe
prevention and treatment of burn wound infections [5,12–17].
Another benefit of topical agents is that they can be delivered
directlytothesiteofcolonizationor infectionandcanbeusedfor
both the prophylaxis and treatment of burn wound infections
[18].Agentssuchassilversulfadiazine, silvernitrate,mupirocin,
honey, mafenide acetate, and neomycin have been in use for
years with variable amounts of objective data available to
support their use (Table 1).
Though we have in vitro data about the topical antibiotics’
general spectrum of activity, there are no established clinical
breakpoints to determinewhether an isolate is susceptible to a
particular agent at concentrations expected at the wound
surface. Bacteria with resistance to multiple systemic anti-
microbials are increasing in prevalence worldwide, which
raises concern for a subsequent increase in resistance to
topical agents. The potential for resistant isolates makes
choosing empiric systemic antimicrobial therapy in the burn
unit more challenging and may reduce the number of
available treatment options. Thus, the possibility of using
topical agents for prophylaxis and treatment of burn wound
infections is appealing, in particular given the ability to apply
topical agents directly at the site of infection, avoiding
potential systemic toxicities and the risk of systemic anti-
biotics not arriving through avascular tissue to the site of
infection. However, some previous studies have already noted
concern for resistance to topical agents as well to include
emerging resistance of staphylococci to mupirocin and
of Pseudomonas aeruginosa to silver sulfadiazine (Table 1)
[9,18–21].
Prior studies assessing topical agent antimicrobial resis-
tance profiles have used agar well diffusion and broth
microdilution methods with data indicating an increase in
resistance of MDR pathogens to topical antimicrobials as
compared to non-MDR pathogens [8,22–24]. However, there
are limited data comparing strain variability and systemic
antimicrobial resistance to topical antimicrobial activity
tested by various methods.
With MDR bacteria on the rise we designed this study to
compare selected bacterial isolates against various topical
antimicrobial agents using two methods, broth microdilution
and agar well diffusion, in conjunction with phenotypic and
genotypic testing to evaluate for clonal differences in activity
and correlation with systemic resistance profiles and topical
agent activity.
2. Methods
2.1. Bacterial isolates
A collection of bacterial isolates were obtained from patients
admitted to the US Army Institute of Surgical Research
(USAISR) Burn Center. The USAISR Burn Center is a 40-bed
unit located within Brooke Army Medical Center that serves
Department of Defense beneficiaries worldwide and the
civilian population from within the southern Texas regional
trauma system. Standard burn patient care includes resusci-
tation and stabilization upon arrival with early burn wound
excision and skin grafting. Vancomycin and amikacin are
administered routinely peri-operatively and various topical
antimicrobials are used to include silver sulfadiazine, mafe-
nide acetate, silver nitrate solution, and silver-impregnated
dressings. The choice of the specific topical agent used is at
staff discretion. Aggressive infection control is practiced in the
center to include individual patient rooms, use of contact
precautions, and strictly enforced handwashing.
The most common gram-negative pathogens recovered in
our burn unit are Acinetobacter baumannii-calcoaceticus complex
(ABC), extended-spectrum beta-lactamase (ESBL) producing
Klebsiella pneumoniae, and P. aeruginosa, with methicillin-
resistant Staphylococcus aureus (MRSA) being a common
gram-positive organism isolated. Isolates studied had been
saved for performance improvement purposes and were
stored in Microbank1 Bacterial Preservation systems (Pro-
Lab Diagnostics, Austin, TX) at 20 8C. The P. aeruginosa
isolates were stored at room temperature on agar deeps.
Isolates were passed twice on TrypticaseTM Soy Agar with 5%
Sheep Blood (TSA II) (BD Diagnostic) prior to use. Quality
control (QC) bacteria (Escherichia coli ATCC1 25922, Enterococcus
faecalis ATCC1 29212, P. aeruginosa ATCC1 27853, and S. aureus
ATCC1 29213) were obtained from the American Type Culture
Collection (Manassas, VA). The QC organisms were main-
tained and cultured in the samemanner as the test organisms.
2.2. Antimicrobial susceptibility testing
Using the Phoenix Automated Microbiology System (Becton,
Dickinson and Co., Franklin Lakes, NJ) standard systemic
antibiotic profiles were determined [25]. For P. aeruginosa and
ABC,wedefinedMDRas resistance toall antimicrobials tested in
a group for 3 ormore groups among the aminoglycosides, beta-
lactams, carbapenems, and fluoroquinolones [26]. All of the K.
pneumoniae isolates used in this study were ESBL-producing. All
of the S. aureus isolates were methicillin-resistant.
2.3. Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) was also performed for
further clonal typing as described elsewhere [27–29]. The
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Table 1 – Description of topical antimicrobial agents evaluated.
Topical agent Mechanism of action Spectrum of activity Pros Cons Resistance/
other
Prior studies
Bacitracin Polypeptide produced by Bacillus
subtilis that inhibits cell wall
synthesis and disrupts the
cytoplasmic membrane by
forming a complex with C55-
prenol pyrophosphate[8,9]
Gram-positive organisms
especially Staphylococci and
beta-hemolytic Streptococci [8]
Inactive against most gram-
negative organisms including P.
aeruginosa [34]
Minimal absorption Rare anaphylaxis
and allergic contact
dermatitis [9]
Rare resistant S.
aureus [9]
None available
Medical
grade honey
Variable antimicrobial activity
among honeys collected from
natural environments [7]
Properties responsible for
antimicrobial activity include
high osmolarity, low pH (3.2–
4.5), a thermolabile substance
called inhibine, and production
of hydrogen peroxide [7,35]
Also may have some anti-
inflammatory activity [36]
Bactericidal against gram-
positive and gram-negative
organisms including P.
aeruginosa and MRSA [35,37]
Manages superficial bacteria but
may also diffuse through skin to
deeper tissues [36]
Generally found to be soothing,
pain-relieving, and non-
irritating [36]
May promote healing of burn
wounds and reduce scarring [35]
Food-grade honey is not a
sterile product; may contain
Bacillus spp. [38] Medical-grade
honey needs to be filtered and
gamma-irradiated
Avoid use in patients with
allergy to honey, bee products,
or bee stings [36]
No reported
resistance [7]
Honey helped burn
wounds to heal
earlier and with
fewer complications
than convention
treatment (silver
sulfadiazine) [35]
Most data available is
on Leptospermum spp.
honey (Manuka)
Mafenide
acetate
(Sulfamylon)
Inhibits nucleotide synthesis [8] Bacteriostatic against gram-
negative organisms including P.
aeruginosa and gram-positive
organisms [13,39]
11.1% cream, 5% solution
Rapidly penetrates full
thickness eschar making it
effective in heavily colonized
wounds and established burn
wound infection [3,5,33]
11.1% concentration is painful
when applied to the superficial
partial-thickness burns with
intact free nerve endings [3,40]
Can dry into a tenacious gum
(neoeschar) that attaches to the
wound requiring hydrotherapy
to remove [41]
5% aqueous solution is less
painful and does not leave a
residue [42]
Absorbed systemically with
highest blood levels of mafenide
and its metabolite (p-
carboxybenzenesulfonamide) in
2nd–4th hour resulting in
urinary alkalinization from
carbonic anhydrase inhibition
[43]
Possible metabolic acidosis,
especially in patients with
pulmonary dysfunction such as
atelectasis or pneumonia that
limits respiratory compensation
[14,40,44]
Electrolyte disturbances [45]
7% incidence of
hypersensitivity, usually a rash
[5]
Rapid absorption from the
tissue requires twice daily
application to keep levels high
enough for bacterial inhibition
[33]
No resistance
reported to P.
aeruginosa [6]
Some resistance
described to
Providencia [5]
Mortality benefit in
prevention of burn
wound sepsis
described in animal
models [13]
Reduction in
mortality and the rate
of invasive burn
wound infections in
patients from before
the introduction of
mafenide to after,
particularly in
patients with 40–79%
TBSA in one study [5]
and between 20 and
59% TBSA in another
study [14,15]
Found to be the most
effective topical agent
against A. baumannii
[18]
Poor correlation
between broth
microdilution and
agar well diffusion
[23]
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Mupirocin Pseudomonic acid, produced by
Pseudomonas fluorescens [19]
Inhibition of RNA and protein
synthesis by targeting the
isoleucine-binding site on the
isoleucyl-transfer-RNA
synthetase enzyme [9,46,47]
Bactericidal at high
concentrations (2% formulation)
and after 24–36 h of exposure
[46]
Highly active against
streptococci and staphylococci
including MRSA [9]. Not active
against enterococci
Less effective against most
gram-negative bacilli and
anaerobes including K.
pneumoniae and P. aeruginosa [19]
No systemic absorption of
mupirocin or its major
metabolite (monic acid) has
been detected with topical use
in healthy volunteers or
patients with epidermolysis
bullosa [9,46]
Can penetrate eschar [48]
Has been used successfully in
the treatment of MRSA-infected
burns wounds [49]
Prolonged use may result in
overgrowth of non-susceptible
organisms, including fungi [9]
Emergence of
resistant
staphylococci has
been described
worldwide [9,19,20]
Possible mechanism
of resistance is a
transmissible
plasmid [46]
No cross resistance
with other antibiotics
[50]
Application of
mupirocin to burn
wounds rapidly
eradicated MRSA [48]
Good correlation
between broth
microdilution and
agar well diffusion
[23]
Neomycin Aminoglycoside produced by
Streptomyces fradiae [51]
Inhibition of protein synthesis
at the 30S subunit of the
bacterial ribosome [9]
May also inhibit bacterial DNA
polymerase
Gram-negatives except
Pseudomonas aeruginosa and
anaerobes such as Bacteroides
spp. [51]
Staphylococci, not Streptococci and
gram-positive bacilli
May enhance re-
epithelialization in wound
healing [34]
Otoxicity and nephrotoxicity
with systemic use. Absorption
can occur through inflamed
skin but is negligible through
normal skin [9,51]
Allergic sensitization especially
when ointment is used for
prolonged time on inflamed or
denuded skin [51]. Related to
mast cell degranulation and
histamine release [9]
Resistant strains of E.
coli, Klebsiella, and
Proteus spp. may
emerge [51]
Transfer of neomycin
resistance occurs in
hospital-acquired
isolates of S. aureus
Resistance may be
plasmid mediated,
and resistance to
other
aminoglycosides can
be transferred on the
same plasmid [9]
None available
Polymyxin B Inhibits activity of endotoxins
[52]
Interacts with the outer
membrane of the gram-
negative cell wall and destroys
bacterial membranes with a
detergent-like mechanism [8,52]
Gram-negative organisms
including P. aeruginosa [8]
No activity against gram-
positive organisms or fungi [9]
Little systemic absorption [9] No data available Resistant strains of A.
baumannii are
emerging [18]
None available
Silver nitrate Interferes with electron
transport inhibiting cellular
respiration and function [8,17]
Gram-negative and gram-
positive organisms including
Pseudomonas spp. and S. aureus
[8,53]
Some activity against Candida
spp.
0.5% aqueous solution
Reduces nutritional and
metabolic losses by decreasing
evaporative water loss [3,33,54]
Painless on application [33]
Poor eschar penetration [3] so
can be used for prophylaxis but
not treatment of burn wound
infections [55]
Turns black upon contact with
tissues and can stain linens
[53,54,56,57]
Electrolyte disturbances due to
leeching of cations across the
wound into the hypotonic
solution, ‘‘sodium sink’’
[3,6,20,33,40,54]
Aerobacter cloacae and some
other gram-negative bacteria
can convert the nitrate to nitrite
causing methemoglobinemia [3]
Problems with tissue irritation
and delayed wound healing
have been reported [3,57]
Acquired resistance is
uncommon [33,58]
Resistance is often
unstable and isolates
can revert back to
sensitive [59]
Has been used in
burn treatment since
at least the 18th
century, initially in a
hardened form called
lunar caustic [10]
Reduced mortality in
burned mice with P.
aeruginosa infection
by 30% [16]
Application to >40%
TBSA wounds
delayed sepsis and
reduced mortality
from 81% to 33% [54]
b
u
r
n
s
3
6
(2
0
1
0
)
1
1
7
2
–
1
1
8
4
1
1
7
5
Table 1 (Continued )
Topical agent Mechanism of action Spectrum of activity Pros Cons Resistance/
other
Prior studies
Silver Sulfadiazine
(Silvadene)
Interferes with electron
transport and nucleotide
synthesis [8]
Binds to bacterial cell
membranes and cell wall,
penetrates the cell, and
denatures bacterial DNA and
RNA resulting in inhibition of
replication [9,17]
Bactericidal to gram-negative
and gram-positive organisms
including Pseudomonas spp. and
S. aureus (MRSA) [3,20]
Some activity against Candida
spp. and herpesviruses at high
concentrations [9]
Combination of the silver ion
and sulfadiazine in a 1% water
soluble cream introduced in
1968 [3]
Painless on application [60]
Accelerated deep dermal wound
healing and reduced conversion
rate of deep dermal wounds to
full-thickness skin wounds [17]
Delayed eschar separation [17]
Poor eschar penetration
Reversible granulocyte
depression especially in >30%
TBSA burns [3,6,9]. This occurs
early in therapy (postburn day
2) and mainly affects mature
neutrophils though has not
been shown to increase risk of
infectious complications [61]
Not very effective in established
infection due to minimal eschar
penetration [49]
Appears as a thick creamy
exudates on the wound, which
can be confused with pus [3,53]
Rare hypersensitivity reactions
to sulfa moiety reported [33,62]
and rare hemolysis in setting of
G6PD deficiency [21]
Systemic absorption especially
in more vascular partial-
thickness burns [21,63] though
an experimental model using
radioactive silver sulfadiazine
showed silver only in the skin
and not in the blood/organs [53]
Rare argyrosis [63] if silver levels
are many times normal [21]
Resistant to most
Enterobacter cloacae
and some
Pseudomonas spp. [5]
Plasmid-mediated
resistance against
some gram-negatives
including A.
baumannii and P.
aeruginosa has been
reported in burn
patients [9,18,21]
Reduced mortality in
burned mice with P.
aeruginosa infection
by 60–75% [16]
Poor correlation
between broth
microdilution and
agar well diffusion
[23]
Triple antibiotic
ointment (Neomycin,
Polymyxin B, bacitracin)
Antimicrobial activity has been
shown to reside in the
neomycin component [52]
Moderate activity against a
variety of burn isolates, but has
poor activity against P.
aeruginosa [52]
No data available No data available No data available None available
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Table 2 – Pulsed-field type, broth microdilution, agar well diffusion, and antibiotic resistance profiles for methicillin-resistant Staphylococcus aureus isolates from burn
patients.
MRSA Broth microdilution Agar well diffusion Systemic antimicrobial agents
PFT MIC BAC MUP NEO POL SN SS MA H AWD BAC MUP B/N/P SN SS MA H Susc Clin Ery Gent Levo Lin Mox Q/D Rif Tet T/S Vanc
1 >256 1 64 32 8 32 1024 5 9 150 9 12 22 34 22 R R S R S R S S S S S
1 >256 2 128 16 8 32 1024 5 9 150 9 13 22 34 21 R R S R S I S S S S S
1 >256 2 64 32 16 32 1024 10 9 62 9 13 23 36 23 R R S R S I S S S S S
1 >256 1 32 16 8 32 512 5 9 150 9 11 23 35 23 R R S S I S S S S S S
1 >256 >128 64 16 16 32 512 15 9 38 9 12 22 33 23 X R R R S R S S S S S
1 >256 1 64 16 16 32 1024 5 9 150 9 13 21 36 22 R R S R S S S S S S S
1 >256 1 64 16 16 32 1024 10 9 150 9 12 21 33 22 X R S R S I S S S S S
1 >256 2 >1024 16 8 32 512 20 9 150 9 13 23 34 23 X R S R S R S S S S S
1 >256 1 256 16 16 32 512 5 9 150 9 13 24 34 22 X R S R S R S S S S S
1 >256 1 64 16 16 32 512 10 9 150 9 12 22 32 24 R R S R S I S S S S S
1a >256 2 128 16 32 64 1024 15 9 150 9 12 23 31 22 X R S R S R S S S S S
1c >256 1 128 16 8 32 1024 5 9 150 9 13 24 34 23 X R S R S I S S S S S
1c >256 1 32 32 8 32 512 15 9 150 9 13 23 34 23 R R S R S I S S S S S
3 >256 2 32 16 16 64 1024 15 9 150 9 13 21 33 24 R R S S S S I S S S S
4 32 0 256 32 16 32 1024 5 9 150 9 12 21 28 21 S S R R S S S S R R S
USA 300 >256 0.12 16 64 16 32 1024 15 9 150 9 12 23 33 22 X R S I S S S S S S S
USA 300 >256 0.12 512 64 16 32 1024 10 9 150 9 12 23 32 23 X R S S S S S S I S S
USA 300 >256 0.25 >1024 16 16 32 1024 15 9 150 9 13 22 31 23 X R S S S S S S I X S
USA 300 >256 0.12 512 32 16 64 1024 15 9 150 9 12 23 36 23 X R S S S S S S S S S
USA 300 32 0.12 <0.5 16 16 32 512 5 9 150 20 13 25 36 24 S S S S S S S S S S S
mg/ml mm
50 >256 1 64 16 16 32 1024 10 Mean 9 140 9.6 12.5 22.6 33.5 22.7 %susc 20 10 90 30 95 45 95 100 85 95 100
90 >256 2 512 32 16 64 1024 15 Range 9 38–150 9–20 11–13 21–25 28–36 21–24
50 = MIC50 = minimum concentration required to inhibit growth of 50% of isolates tested; 90 = MIC90 = minimum concentration required to inhibit growth of 90% of isolates tested; PFT = pulsed field
type; MIC = minimum inhibitory concentration; BAC = bacitracin; MUP = mupirocin; NEO = neomycin; POL = polymyxin; SN = silver nitrate; SS = silver sulfadiazine; MA = mafenide; H = honey;
AWD = agar well diffusion; B/N/P = bacitracin, neomycin, polymyxin in triple antibiotic ointment; Susc = antimicrobial susceptibilities; Clin = clindamycin; Ery = erythromycin; Gent = gentamicin;
Levo = levofloxacin; Lin = linezolid; Mox = moxifloxacin; Q/D = quinupristin/dalfopristin; Rif = rifampin; Tet = tetracycline; T/S = trimethoprim/sulfamethoxazole; Vanc = vancomycin; %susc = %
susceptible out of those isolates tested against a specific antimicrobial agent; R = resistant; S = susceptible; I = intermediate susceptibility; X = not tested.
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Table 3 – Pulsed-field type, broth microdilution, agar well diffusion, and antibiotic resistance profiles for Klebsiella pneumoniae isolates from burn patients.
Kleb Broth microdilution Agar well diffusion Antimicrobial susceptibility
PFT MIC BAC MUP NEO POL SN SS MA H AWD BAC MUP B/N/P SN SS MA H Susc Ami Gent Tobra Cefep Ceftaz P/T Levo Cipro Imi Mero
1 >256 >128 1 2 16 64 1024 25 9 32 18 12 22 26 16 S R I R X X R R S S
1C >256 >128 1 <0.5 8 32 512 25 9 27 19 12 20 27 17 S R I R R S R R S S
1C >256 >128 2 16 16 64 2048 20 9 30 17 11 18 23 16 S R R R X I R R S S
1C >256 >128 <0.5 <0.5 8 32 1024 25 9 32 20 13 21 27 17 S R I R R I R R S S
1C >256 >128 <0.5 1 8 32 1024 25 9 28 18 12 18 25 16 S R I R R R R R S S
1D >256 >128 <0.5 <0.5 8 32 512 25 9 27 18 6 9 25 17 R R R R R R R R S S
2 >256 >128 1 <0.5 8 32 1024 25 9 27 20 8 15 29 17 R R R R X R R R S S
2 >256 >128 <0.5 16 8 32 1024 25 9 34 19 13 21 25 17 R R R R X R R R S S
2 >256 >128 1 32 8 32 1024 25 9 36 20 13 20 23 19 R R R R R X S I S S
2B >256 >128 1 32 16 64 1024 25 9 31 21 12 21 23 18 S R I R R R R R S S
2C >256 >128 <0.5 <0.5 8 32 1024 25 9 31 17 6 12 24 17 S R R R R I S R S S
2C >256 >128 <0.5 <0.5 8 32 2048 25 9 33 20 6 12 23 17 S R R R R R S R S S
2C >256 >128 <0.5 <0.5 8 32 512 25 9 24 17 6 9 32 18 S R R R R X R R S S
38 >256 >128 32 8 8 32 2048 25 9 43 9 9 21 23 18 R R R R R S S S S S
3B >256 >128 <0.5 16 8 32 2048 25 9 37 21 15 20 20 17 S R R R R R S R S S
5 >256 >128 2 2 8 32 1024 25 9 33 15 10 20 21 16 S R R R R R S R S S
10 >256 >128 <0.5 1 8 32 2048 25 9 30 17 10 18 19 16 S R R R R R R R S S
16 >256 >128 2 2 16 64 2048 25 9 28 16 10 18 26 16 S R R R R R S R S S
17 >256 >128 <0.5 16 8 32 2048 20 9 29 21 12 21 20 18 R R R R R X R R S S
18 >256 >128 2 <0.5 32 32 2048 20 9 31 15 9 15 14 17 S R R R R X R R S S
18A >256 >128 2 16 16 32 1024 20 9 34 16 8 13 21 17 R R R R R X S S S S
24 >256 >128 <0.5 1 8 32 2048 25 12 28 17 11 16 21 16 S R R R R R S S S S
mg/ml mm
50 >256 >128 <0.5 1 8 32 1024 25 Mean 9.1 31.1 17.8 10.2 17.3 23.5 17 %susc 68 0 0 0 0 13 41 14 100 100
90 >256 >128 2 16 16 64 2048 25 Range 9–12 24–43 9–21 6–15 9–22 14–32 16–19
50 = MIC50 = minimum concentration required to inhibit growth of 50% of isolates tested; 90 = MIC90 = minimum concentration required to inhibit growth of 90% of isolates tested; PFT = pulsed field
type; MDRO = multidrug resistant organism; MIC = minimum inhibitory concentration; BAC = bacitracin; MUP = mupirocin; NEO = neomycin; POL = polymyxin; SN = silver nitrate; SS = silver
sulfadiazine; MA = mafenide; H = honey; AWD = agar well diffusion; B/N/P = bacitracin, neomycin, polymyxin in triple antibiotic ointment; Susc = antimicrobial susceptibilities; Ami = amikacin;
Gent = gentamicin; Tobra = tobramycin; Cefep = cefepime; Ceftaz = ceftazidime; Pip/tazo = pipericillin/tazobactam; Levo = levofloxacin; Cipro = ciprofloxacin; Imi = imipenem; Mero = meropenem;
%susc = % susceptible out of those isolates tested against a specific antimicrobial agent.
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Table 4 – Pulsed-field type, broth microdilution, agar well diffusion, and antibiotic resistance profiles for Pseudomonas aeruginosa isolates from burn patients.
PS Broth microdilution Agar well diffusion Antimicrobial agents
PFT MDRO MIC BAC MUP NEO POL SN SS MA H AWD BAC MUP B/N/P SN SS MA H Susc Ami Gent Tobra Amp/S Cefep Ceftaz P/T Levo Cipro Imi Mero
1 Yes >256 >128 16 2 8 32 1024 10 9 17 9 9 15 26 18 S S S R R R R R R R R
1 Yes >256 >128 16 4 8 32 1024 10 9 20 9 11 20 33 21 S R S X R R X R R R I
1 No >256 >128 8 2 8 32 2048 10 9 22 10 11 16 27 15 S S S R R R R R R S S
1 Yes >256 >128 16 1 8 32 1024 10 9 18 10 10 15 10 17 S I S R R R R R R R R
1A Yes >256 >128 16 1 8 16 1024 10 9 18 9 9 17 26 15 S I S R R R R R R R R
1A Yes >256 >128 8 2 8 32 1024 10 9 23 10 10 16 30 19 S S S R R R R R R R I
2 No >256 >128 4 2 8 16 1024 10 9 17 13 14 20 27 18 S S R R R S R R R R R
2 No >256 >128 4 2 8 16 1024 10 9 16 13 14 25 34 15 S S I R R S R R R R R
2 No >256 >128 4 2 8 16 1024 10 9 18 15 14 20 27 16 S S R R R S R R R R R
3 No >256 >128 4 2 8 16 512 15 9 16 12 14 24 35 14 S S S R S S S S S S S
3 No >256 >128 4 2 8 16 256 15 9 17 11 15 22 34 16 S S S R S S S S X S S
4 Yes >256 >128 32 2 8 16 128 10 9 21 9 15 23 15 22 S S S R I R R R R R R
5 No >256 >128 8 1 8 16 512 15 9 19 13 15 25 37 13 S S S R S S S S S S S
6 Yes >256 >128 8 1 8 16 1024 10 9 21 9 14 20 29 15 I I S R R R R R R R I
7 No >256 >128 32 2 8 16 1024 10 9 21 9 14 20 14 17 S R S R S R R R R R I
8 No >256 >128 16 1 8 16 256 10 9 14 9 13 18 40 18 S R S R R R R R R I S
9 No >256 >128 4 2 8 16 512 15 9 18 9 15 23 36 14 S S S R S S S S S S S
10 Yes >256 >128 8 1 8 16 128 15 9 18 9 11 15 11 17 S S S R I R R R R R R
11 No >256 >128 8 2 8 16 512 10 9 23 14 15 23 44 16 S S S X S S X S S S S
12 Yes >256 >128 32 2 8 32 256 10 9 21 9 7 15 42 17 R R R R R R R R R R R
mg/ml mm
50 >256 >128 8 2 8 16 1024 10 Mean 9 18.9 10.6 12.5 19.6 28.9 16.7 %susc 90 65 80 0 30 40 22 25 21 30 35
90 >256 >128 32 2 8 32 1024 15 Range 9 14–23 9–15 7–15 15–25 10–44 13–22
50 = MIC50 = minimum concentration required to inhibit growth of 50% of isolates tested; 90 = MIC90 = minimum concentration required to inhibit growth of 90% of isolates tested; PFT = pulsed field
type; MDRO = multidrug resistant organism; MIC = minimum inhibitory concentration; BAC = bacitracin; MUP = mupirocin; NEO = neomycin; POL = polymyxin; SN = silver nitrate; SS = silver
sulfadiazine; MA = mafenide; H = honey; AWD = agar well diffusion; B/N/P = bacitracin, neomycin, polymyxin in triple antibiotic ointment; Susc = antimicrobial susceptibilities; Ami = amikacin;
Gent = gentamicin; Tobra = tobramycin; Amp/S = ampicillin/sulbactam; Cefep = cefepime; Ceftaz = ceftazidime; Pip/tazo = pipericillin/tazobactam; Levo = levofloxacin; Cipro = ciprofloxacin; Imi = i-
mipenem; Mero = meropenem; %susc = % susceptible out of those isolates tested against a specific antimicrobial agent; S = susceptible; R = resistant; I = intermediate susceptibility; X = not tested.
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relatedness of ABC, MRSA, P. aeruginosa, and K. pneumoniae
isolateswas determined by PFGE as previously described using
a CHEF-DRIII system (Bio-Rad Laboratories, Hercules, Califor-
nia) [27–29]. The endonuclease Apa I was used for ABC PFGE,
Sma I for MRSA PFGE, Xba I for K. pneumoniae PFGE, and Spe I for
P. aeruginosa PFGE. Gel images were analyzed using BioNu-
merics software (Applied Maths, Austin, TX). PFGE profiles
were compared using the Dice coefficient and grouped into
pulsed field types using established criteria [30].
2.4. Broth microdilution assay
Minimum inhibitory concentrations (MIC) of tested com-
pounds were determined using custom prepared 96-well MIC
panels (Trek Diagnostic, Cleveland, OH), within the following
concentration ranges: bacitracin, 0.12–256 mg/ml; mupirocin,
0.06–128 mg/ml; neomycin, 0.5–1024 mg/ml; polymixin B, 0.5–
1024 mg/ml; silver nitrate, 0.12–256 mg/ml; silver sulfadiazine,
2–4096 mg/ml; mafenide acetate, 16–4096 mg/ml; and medical
grade honey, 0–50%. The panels were thawed at room
temperature and inoculated with a 95 pin disposable inocula-
tor, according to themanufacturer’s directions. To prepare the
inoculum, fresh overnight cultures were suspended in sterile
deionized water to meet a 0.5 McFarland standard. One
milliliter of the cell suspension was pipetted into 29 ml of
sterile deionized water and vortexed. The 30 ml cell suspen-
sion was poured into the inoculation tray and the 95 pin
inoculatorwas placed into the inoculation traywith the empty
pin spot aligned with the negative growth control well on the
panel. The inoculators were then removed and discarded. The
MICpanelwas incubated at 37 8C for 24 h. After incubation, the
panels were scored for growth. A button of 2 mmor larger was
considered positive for growth. All isolates and drugs were
tested in duplicate. If there was a greater than 2 dilution
difference between each test for an individual isolate, the
experiment was repeated. When reporting the data, the first
run isolate that was within 2 dilutions of the other isolate was
used. For each antimicrobial agent, the MIC50 and MIC90 were
determined. The MIC50 was defined as the minimum concen-
tration required to inhibit growth of 50% of the isolates tested.
Likewise, the MIC90 was defined as the minimum concentra-
tion required to inhibit growth of 90% of the isolates tested.
2.5. Agar well diffusion
All isolates were tested against the following commercial
topical antimicrobial agents: bacitracin ointment 500 U/g
(Perrigo, Allegan, MI), mafenide acetate cream 85 mg/g (UDL
Laboratories Inc., Rockford, IL), 2% mupirocin ointment (Clay-
Park Labs Inc., Bronx, NY); 0.5% silver nitrate solution (Teva
Pharmaceutical, Sellersville, PA), 1% silver sulfadiazine cream
(Par Pharmaceutical Inc., Spring Valley, NY), and triple
antibiotic ointment containing bacitracin zinc (400 bacitracin
units), polymyxin B sulfate (5000 polymyxin B units), and
neomycin sulfate (5 mg, 3.5 mg neomycin base) (E. Fougera &
Co., Melville, NY), and medical grade honey (Active Manuka
Honey, USA). All of the antimicrobial agents except for silver
nitrate were assayed using the Nathan agar well diffusion
method [22]. The silver nitrate was tested by standard disk
diffusion [31]. Briefly, 9 mm wells were made in Mueller-
Hinton II agar plates using a sterile bore and then filled with
0.25 ml of antimicrobial agent. All of the wells were then
sealed with 2–3 drops of 1.5% agar. The plates were inoculated
using the agar overlay method [32]. Using fresh overnight
cultures, a cell suspensionwasmade in normal saline tomake
a 0.5 McFarland standard. A melted (45–50 8C) 9.0 ml 1.5% agar
blank was then inoculated with 1 ml of the cell suspension,
mixed gently by inversion, and then poured over the Mueller-
Hinton agar plates. Once the agar overlay had solidified, 6 mm
paper disks (BD BBL, Franklin Lakes, NJ) containing 10 ml of the
silver nitrate solution were placed on the agar overlay. The
plates were incubated for 24 h at 37 8C. Following incubation,
the zones of inhibition were measured to the nearest
millimeter. All agents and isolates were tested in duplicate.
If there was a greater than 3 mm difference in zone size
between the first and second test for a particular isolate, the
experiment was repeated for that particular antimicrobial
agent. When reporting data, the first run experiment with
results within 3 mm of the other was reported. The average
zone of inhibition size was calculated for each agent and
reported as a mean and range.
3. Results
Twenty isolates each of ABC, P. aeruginosa, and MRSA, and 22
isolates of K. pneumoniae from patients in the burn center were
obtained from the hospital laboratory. Most of the isolates of
each species were from a unique patient though one patient
had two ABC isolates included. The isolates were from blood,
skin and wounds, cerebrospinal fluid, and respiratory sites.
The isolates were classified into clonal type based on pulsed-
field gel electrophoresis data. ABC and P. aeruginosa were
categorized as MDR or not based on susceptibilities to
systemic antimicrobial agents (Tables 2–5). Forty-five percent
of the P. aeruginosa isolates and 75% of the ABC isolates were
categorized as MDR. All of the K. pneumoniae isolates were
ESBL-producers.
For each antimicrobial agent, the MIC50 and MIC90 were
determined from the broth microdilution results and the
mean zones of inhibition were calculated from the agar well
diffusion (Tables 2–5). For MRSA (Table 2), 18/20 isolates (90%)
had MICs of >256 mg/ml to bacitracin and mafenide acetate
had MICs ranging from 512 to 1024 mg/ml, with the MIC50 and
MIC90 both 1024 mg/ml. Neomycin had wide range of MICs,
from <0.5 to >1024 mg/ml. The topical antimicrobials contain-
ing silver, silver nitrate and silver sulfadiazine, had MICs
ranging from 8 to 16 mg/ml with silver nitrate and from 32 to
64 mg/ml for silver sulfadiazine. Polymyxin B also had a
moderate range of MICs, from 16 to 64 mg/ml, with MIC50 of
16 mg/ml and MIC90 of 32 mg/ml. The MICs for honey against
MRSA ranged from 5 to 20 mg/ml. Mupirocin had the lowest
range of MICs for MRSA, with MIC50 of 1 mg/ml and MIC90 of
2 mg/ml, making it the most active agent against MRSA by the
broth microdilution method. Similarly, by the agar well
diffusion method, mupirocin overall had very large zones of
inhibition of 150 mm (the size of the plate) making it the
topical agent with the best parameters for MRSA by both
methods. Zones of inhibition for the silver-containing agents,
again, were in themoderate range, withmafenide acetate and
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Table 5 – Pulsed-field type, broth microdilution, agar well diffusion, and antibiotic resistance profiles for Acinetobacter baumannii-calcoaceticus complex isolates from burn
patients.
ABC Broth microdilution Agar well diffusion Antimicrobial agents
PFT MDRO MIC BAC MUP NEO POL SN SS MA H AWD BAC MUP B/N/P SN SS MA H Susc Ami Gent Tobra Cef Ceft Pip Levo Cip Imi Mero
1 Yes >256 >128 64 <0.5 8 16 1024 15 9 18 15 6 19 27 18 R R R X S R R R R R
1 Yes >256 >128 8 1 8 16 1024 15 9 16 9 10 13 22 20 R R R X I R I R R R
1 Yes >256 >128 16 <0.5 8 16 1024 15 9 19 9 10 14 22 21 R R R X S R I R R R
1 Yes >256 >128 16 <0.5 8 16 1024 15 9 16 9 10 14 23 19 R R R X S R I R R R
1 Yes >256 >128 32 2 8 32 2048 15 9 16 9 11 14 23 21 R R R X S R R R R R
2 Yes >256 >128 32 <0.5 8 16 1024 20 9 20 9 9 16 28 18 R R R X R R R R S S
3 No >256 >128 32 1 8 16 1024 20 9 20 9 13 19 25 17 S S S X R R S S S S
4 No >256 >128 4 1 8 32 2048 10 9 16 9 11 19 24 18 S R S X R R R R S S
5 Yes >256 >128 64 1 8 16 1024 20 9 22 9 11 18 22 18 R R S R R R R R R R
5 Yes >256 >128 64 <0.5 8 32 2048 20 9 22 9 12 19 23 17 R R I X R R R R R R
5 Yes >256 >128 64 <0.5 8 32 1024 20 9 22 9 10 20 24 17 R R R R R X R R R R
7 Yes >256 >128 32 <0.5 8 16 2048 20 9 21 9 12 21 30 22 R R I X R R R R R R
7 Yes >256 >128 256 1 8 16 1024 20 9 23 9 11 19 25 18 R R S X R R R R R R
13 No >256 >128 1024 <0.5 8 32 2048 20 9 20 9 10 19 23 18 S R S X R R R R S S
14 Yes >256 >128 128 1 16 32 1024 20 9 20 9 11 20 28 18 I R R R R X R R R R
18 Yes >256 >128 32 <0.5 8 16 2048 15 9 22 9 9 15 34 21 R R R X R R R R S S
18 Yes >256 >128 >1024 <0.5 8 16 2048 10 9 16 9 10 15 32 20 R R R X R R R R S X
33 No >256 >128 32 1 8 4 256 20 9 19 21 10 25 34 16 S S S X S R S I S S
36 No >256 >128 2 <0.5 8 16 512 20 9 20 9 11 19 22 19 S R S X S R S R S S
38 Yes >256 >128 32 <0.5 8 32 4096 20 9 20 9 12 19 24 20 R R S X R R R R R R
mg/ml mm
50 >256 >128 32 <0.5 8 16 1024 20 mean 9 19.4 9.9 10.5 17.9 25.8 18.8 %susc 25 10 40 0 30 0 15 5 40 37
90 >256 >128 256 1 8 32 2048 20 range 9 16–23 9–21 6–13 13–25 22–34 16–22
50 = MIC50 = minimum concentration required to inhibit growth of 50% of isolates tested; 90 = MIC90 = minimum concentration required to inhibit growth of 90% of isolates tested; PFT = pulsed field
type; MDRO = multidrug resistant organism; MIC = minimum inhibitory concentration; BAC = bacitracin; MUP = mupirocin; NEO = neomycin; POL = polymyxin; SN = silver nitrate; SS = silver
sulfadiazine; MA = mafenide; H = honey; AWD = agar well diffusion; B/N/P = bacitracin, neomycin, polymyxin in triple antibiotic ointment; Susc = antimicrobial susceptibilities; Ami = amikacin;
Gent = gentamicin; Tobra = tobramycin; Amp/S = ampicillin/sulbactam; Cefep = cefepime; Ceftaz = ceftazidime; Pip/tazo = pipericillin/tazobactam; Levo = levofloxacin; Cipro = ciprofloxacin; Imi = i-
mipenem; Mero = meropenem; %susc = % susceptible out of those isolates tested against a specific antimicrobial agent; R = resistant; S = susceptible; I = intermediate susceptibility; X = not tested.
b
u
r
n
s
3
6
(2
0
1
0
)
1
1
7
2
–
1
1
8
4
1
1
8
1
honey also falling into the moderate range by agar well
diffusion. The diffusion zone for bacitracin was 9 mm for all
isolates, meaning that the bacteria grew directly up to thewell,
since 9 mm is the size of the well. For 19/20 isolates (95%), the
triple antibiotic ointment containing bacitracin, neomycin, and
polymyxin B had diffusion zones of 9 mm. There were 7
different pulsed-field types (PFTs) among the 20MRSA isolates,
though there was generally no consistency among the types as
to MICs, zones of inhibition, and antibiotic susceptibility
profiles. The 2 isolates with lower bacitracin MICs were not
the same PFT. One USA300 MRSA isolate had lower MICs to
bacitracin,neomycin,andhoneyandahigherzoneof inhibition
to the triple antibiotic ointment, along with susceptibility to all
systemicantibiotics tested.However, theother 4USA300clones
did not show the same susceptibility profiles.
Resultsdifferedsomewhat for thegram-negativeorganisms,
K. pneumoniae (Table 3), P. aeruginosa (Table 4), andABC (Table 5).
For these organisms, bacitracin again had MICs >256 mg/ml, as
did mafenide acetate. The MIC50 for mafenide acetate for all
organismswas1024 mg/ml. Silvernitrateandsilver sulfadiazine
againhadmoderateMICs,asdidhoney. Incontrast toMRSA, the
MICs for mupirocin for the gram-negative organisms were all
>128 mg/ml. For thegram-negatives,polymyxinBhad lowMICs,
though MICs for neomycin to K. pneumoniae were even lower.
Bacitracinagainhadzonesof inhibitiononagarwelldiffusionof
9 mm indicating growth right up to the well for all gram-
negative isolates, as did most of the isolates against the triple
antibiotic mix. The silver containing agents and honey had
moderately sized zones of inhibition. Mafenide acetate had the
largest average zone of inhibition against both P. aeruginosa and
ABC (Tables4and5); it alsohada largezoneof inhibitionagainst
K. pneumoniae however for that organism, mupirocin had the
largest mean zone of inhibition (Table 3). There were no
statistically significant correlations between MIC and zone of
inhibition (for those agents where correlation could be
performed) except forwith P. aeruginosa and silver sulfadiazine,
where the correlation was weakly negative at 0.65 (p = 0.002)
and with K. pneumoniae and mafenide, where the correlation
was also weakly negative at 0.63 (p = 0.002). It would be
expected to see a negative correlation in this case as theoreti-
cally MICs should decrease with rising zones of inhibition.
Overall, the P. aeruginosa and ABC isolates classified as MDR
using the above definition did not appear to have more
resistance to the topical antimicrobial agents than their non-
MDR counterparts. As with MRSA, there was not consistency
betweenPFTandsusceptibilityprofile.The P. aeruginosa isolates
with highMICs to neomycin were of different PFTs and did not
result in any lower zones of inhibition with the triple antibiotic
ointment.Only2/3of themwereMDR.Thesameapplies forABC
and neomycin, where isolates with the highest MICs to
neomycin were of different PFTs, had the same zone of
inhibitionwith the triple antibiotic ointment, andno significant
difference in resistance to systemic antibiotics.
4. Discussion
In an era of increasing resistance to systemic antimicrobials
necessitating use of second and third line and oftenmore toxic
agents, topical antimicrobial agents are an appealing choice
for burn wound infections, given a theoretical decreased risk
of systemic toxicities and the ability to position the anti-
infective agent directly at the site of the infection, which is
helpful in the setting of the avascularized tissue present in
burn eschar [18]. In addition, early excision and grafting is not
the standard of care worldwide and cannot always be
performed even in our center due to delays in transport from
austere settings to higher echelons of care. In that setting,
topical agents can be very helpful as prophylaxis against burn
wound infection. However, while we can easily obtain data
about the susceptibility profiles of our commonly used
systemic antibiotics, susceptibility information about topical
agents is not readily available to help guide choice of topical
therapy and furthermore, susceptibility breakpoints have not
yet been standardized for these agents.
In this study we determined the susceptibility of topical
antimicrobial agents against bacterial isolates of MRSA, ABC,
ESBL-producing K. pneumoniae, and P. aeruginosa from burn
patients using two previously described methods and com-
pared these susceptibilities against the clonal type of the
organism and susceptibility to systemic antimicrobial agents.
We found that similar to previous studies, mafenide acetate is
the most active agent overall against gram-negatives with
mupirocin most active against MRSA. Silver had moderate
efficacy as well, consistent with prior literature. Unlike other
studies, however, we did not note increased resistance to
topicals associated with MDR isolates vs. non-MDR isolates.
Honey, which has not been evaluated using these techniques
in the prior literature, had both moderate zones of inhibition
and MICs against all of the isolates.
Both the agar well diffusion and broth microdilution
methods have merits and flaws. Broth microdilution has been
found to be more objective and reproducible than agar well
diffusion. However, the agar well diffusion method requires
the agents to diffuse in agar which takes into account their
associated carriers, perhaps better mimicking the activity of
these agents in burn eschar [22]. Neither method truly
accounts for activity of the agents at the level of eschar and
skin and further studies are needed to determine tissue levels.
We found that mupirocin had the best activity against
MRSA, which is not surprising given prior studies on
mupirocin. MICs were high and zones of inhibition were
moderate against P. aeruginosa, which also corroborates with
prior literature indicating that mupirocin is not an ideal anti-
pseudomonal agent. Mafenide acetate was the best agent to
cover all three gram-negative organisms by agarwell diffusion
though by MIC testing, it did not appear as effective. This has
been described in prior studies. While it is concerning that
mafenide acetate does not perform well in vitro, there have
beenmultiple studies in vivo documenting its ability to diffuse
through eschar so one might interpret the large zones of
inhibition as more indicative of mafenide’s performance in
vivo [3,5,23,33]. It is not surprising that zones of inhibition are
scant for bacitracin, as it has been shown previously to not
diffuse well through agar [23]. However, the high MICs also
raise concern that these isolates were resistant even without
the need to diffuse and raises concern about bacitracin being
successfully used in this setting. The triple antibiotic ointment
containing neomycin, polymyxin B, and bacitracin generally
had low-to-moderate zones of inhibition with moderate-to-
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high MICs except in the case of K. pneumoniae. Neomycin has
previously been noted to be themost active component of this
triple therapy and so the fact that the neomycin has the lowest
MICs against K. pneumoniae and the triple antibiotic ointment
has the largest zone of inhibitionwith K. pneumoniae correlates
well with prior reports that neomycin does not have good
activity against P. aeruginosa. The results from honey’s activity
are interesting, in particular because honey is not an agent
currently employed in our burn unit. By broth microdilution,
honey had moderate MICs against all organisms, along with
moderate zones of inhibition by agar well diffusion. Further
research on the antimicrobial properties of honey to deter-
mine its spectrum and mechanism of action are needed as
well as further standardization of medical grade (versus food
grade) honey to ensure safety and reproducible outcomes.
As we move forward in treating burn patients with burn
wound infections it will continue to be important to evaluate
the appropriateness of our choices of topical antimicrobial
therapy as increasing drug resistance ensues. Though our
research did not show that MDR organisms had significantly
different susceptibility profiles than non-MDR organisms, it
was not designed to specifically show that difference since all
of the S. aureus isolates wereMRSA and all of the K. pneumoniae
isolates were ESBL-producers. Future work could be per-
formed to better evaluate whether susceptibility differences
exist betweenMDR and non-MDR organisms in this setting. In
addition, though we have substantial in vitro data describing
the antimicrobial spectrum of activity of these agents, and we
can get a sense of how they, in combinationwith their carriers,
will diffuse in vivo by using the agar well diffuse method, at
this point there is inadequate data describing how well these
agents penetrate normal skin versus eschar in terms of their
ability to obtain therapeutic drug levels. Further clinical
studies with these agents and their carriers on skin and
eschar are needed to ultimately determine standardized
breakpoints so isolates can be classified as susceptible or
resistant to topical agents. Bodies such as the Clinical and
Laboratory Standards Institute (CLSI) should consider devel-
oping guidelines for use of topical agents.
Until we have gained further information, it seems
reasonable to continue to use silver containing agents
empirically for the prophylaxis of burn wound infection and
mafenide acetate for the treatment of likely gram-negative
burn wound infection. Mupirocin appear to be the best choice
if MRSA infection is likely in a specific clinical setting.
Bacitracin appears less effective using these methods while
honey shows promise, althoughmore clinical data are needed
before making substantial changes to clinical practice.
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